Under Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products [OJ L 18, 22.1.2000, p. 1.], medicinal products designated as orphan medicinal products gain ten years of market exclusivity on the granting of a marketing authorisation for the orphan indication. As such products are frequently not patent-protected, the reward of supplementary protection certificate extension cannot be applied; when they are patent-protected, such an extension would provide a double incentive. Therefore, for orphan medicinal products, instead of an extension of the supplementary protection certificate, the ten-year period of orphan market exclusivity should be extended to twelve years if the requirement for data on use in the paediatric population is fully met.
Recital 29, Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…
In forcecited 1×
Order of the General Court (Eighth Chamber), 3 September 2014. Shire Pharmaceutical Contracts Ltd v European Commission.Decision
First, it should be noted that the letter of 2 September 2013 is a response to the applicant’s earlier letter to the Commission of 1 August 2013. In its letter, the applicant simply requested a meeting with the Commission in order to …
3 Sep 2014 · 62013TO0583